DAK,
You may get to ride the rally a little longer, b/c we've entered the "Moron phase."
Diversa, a biocatalytic enzyme developer (loss of $9M on revs of $10M), goes IPO today with a mkt cap of $2.6B. Okay, while they do use genomics and genetic engineering to generate new enzymes this is well removed from human healthcare (they might be used as part of the manufacturing of drugs). In other words, this company is not going to have some dramatic FDA approval make them golden; this is old-fashioned industrial marketing. But that's not what's important, here's what is:
Kao agreed that while Diversa may not be a pure genomics play, she thinks Diversa is attractive to investors because 'the retail investor hears that its a biotech (company) involved with genomics, and that's enough (for them).'
Attention to GLIA, NBIX, <insert your favorite biotech here>:
Forget your business plan. If you have a sequencing gel anywhere in your labs - or if anyone in your labs knows what four nucleotides make up DNA - announce that you're now a genomics company. Please.
Psst! I heard a rumor that CLTR decided they're going to drop the whole silly BLA thing and go into GENOMICS. Oh look, the stock's up already!
biowa genomics
(hey, if celeryroot can go .com...) |
